Skip to main content

Scott Joseph Antonia

Professor of Medicine
Medicine, Medical Oncology

Current Appointments & Affiliations


Professor of Medicine · 2020 - Present Medicine, Medical Oncology, Medicine
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers
Member of the Duke Human Vaccine Institute · 2023 - Present Duke Human Vaccine Institute, Institutes and Centers

In the News


Published October 25, 2022
A New Generation of Tools To Fight Cancer

View All News

Recent Publications


Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.

Journal Article ESMO Open · February 2024 INTRODUCTION: We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced ... Full text Link to item Cite

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Journal Article Lung Cancer · May 2022 OBJECTIVE: In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs). MATERIALS AND METHODS: Patients (N = ... Full text Link to item Cite

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

Journal Article Lancet Oncol · October 2019 BACKGROUND: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cance ... Full text Link to item Cite
View All Publications

Recent Grants


Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029

Role of mregDC-PCSK9-mediated Inhibition of DC Antigen Cross-Presentation in Tumor Immunotherapy Resistance

ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2024 - 2027

Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy

ResearchCo-Principal Investigator · Awarded by National Cancer Institute · 2022 - 2027

View All Grants

Education, Training & Certifications


University of Connecticut, School of Medicine · 1989 M.D.
University of Connecticut, School of Medicine · 1987 Ph.D.